The best of times, the worst of times for psychiatric disease

As long-awaited advances in psychiatric genetics begin to materialize in force, promising to steer us safely to the best of times in psychiatric disease research, many pharmaceutical companies pull away from the challenge of drug development, threatening to bring us to the worst of times for the field. There is a real danger of missed opportunities and a sense of urgency for defining a clear path forward. © 2012 Nature America, Inc. All rights reserved.SCOPUS: re.jinfo:eu-repo/semantics/publishe